MedDataX Logo

Adia MED of Winter Park LLC Autism Spectrum Disorder Research Study

NCT ID: NCT07304440

Last Updated: 2025-12-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2026-01-15

Study Completion Date

2028-06-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This 24-month study is testing whether adding AdiaVita, an umbilical cord blood-derived stem cell and exosome product, to glutathione therapy helps improve autism symptoms in children ages 3-12 more than glutathione alone. Children will be randomly placed into one of two groups for the first three months: one group receives glutathione only, and the other receives glutathione plus monthly intravenous AdiaVita infusions. Both groups also use topical glutathione cream twice daily at home. Autism symptoms will be tracked over two years using the Autism Treatment Evaluation Checklist (ATEC) filled out by parents and by therapists or teachers. Safety, side effects, quality of life, and overall well-being will be closely monitored through regular clinic visits, physical exams, blood tests, and adverse event reporting. After the initial three-month phase, children who received glutathione alone may cross over to receive AdiaVita infusions at no additional cost if safety checks at month 6 are satisfactory. Approximately 100 children with a confirmed autism diagnosis from the Central Florida area will take part. Participation is completely voluntary, and families may withdraw at any time.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study evaluates the safety and preliminary effectiveness of AdiaVita, an umbilical cord blood-derived stem cell and exosome product, when combined with glutathione for improving symptoms of Autism Spectrum Disorder in children ages 3-12. Participants are randomized to receive either glutathione alone or glutathione plus AdiaVita during the initial three-month treatment phase. Symptoms are measured using repeated Autism Treatment Evaluation Checklist assessments completed by both parents and therapists/teachers throughout the 24-month follow-up period. The primary outcome is change in total ATEC scores at Month 6, with secondary outcomes including safety, tolerability, quality of life, and overall wellness. Children in the glutathione-only group may enter a Phase II extension in which they later receive stem cell infusions at no additional cost if safety requirements are met at the six-month interim review. All clinical visits include physical exams, vitals, adverse event reviews, and post-infusion monitoring. Treatments involve monthly intravenous administration and twice-daily at-home topical glutathione during Phase One. Blood tests are completed prior to key visits to ensure medical stability, and serious adverse events trigger immediate medical attention and reporting. Risks include infusion-related discomfort, headache, fever, allergic reactions, or rare immune responses, with theoretical long-term risks noted. Potential benefits include improvement in social interaction, communication, and behavioral symptoms, although no benefits are guaranteed. Participation is voluntary and families may withdraw at any time, though study costs already paid are non-refundable. Data are stored securely with coded identifiers and only authorized parties may access identifiable information. Recruitment occurs through direct contact, clinic advertising, community outreach, and social media. Approximately 100 children from the Central Florida region are expected to participate and must have a confirmed ASD diagnosis prior to enrollment. Exclusion criteria include severe allergies to the study products, uncontrolled medical conditions, and recent participation in another interventional trial. No monetary incentives are offered, and families instead pay a fixed fee of $12,000 for Phase One, which covers all procedures and also includes Phase II if applicable. Outcomes will contribute to scientific knowledge regarding the safety and possible clinical utility of stem cell-based therapies for ASD.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Autism Spectrum Disorder Autism ASD Autism Spectrum Disorder (ASD)

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Glutathione Intravenous glutathione Glutathione therapy Antioxidant therapy Oxidative stress Immune modulation Anti-inflammatory therapy Autism Autism Spectrum Disorder ASD Autism symptoms Stem cell therapy MSCs Mesenchymal stem cells Regenerative medicine Cellular therapy Hematopoietic stem cells (HSCs) Allogeneic stem cells

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Glutathione with Stem Cells

Group Type EXPERIMENTAL

Umbilical Cord Blood-Derived Stem Cells and Exosomes

Intervention Type BIOLOGICAL

Intravenous infusion of cryopreserved allogeneic umbilical cord blood-derived product containing viable mononuclear cells (including hematopoietic and mesenchymal stem/stromal cells) and exosomes.

Glutathione

Intervention Type DRUG

Reduced L-glutathione administered Intravenous infusion once monthly for 3 months (Phase I)

Glutathione Only

Group Type ACTIVE_COMPARATOR

Glutathione

Intervention Type DRUG

Reduced L-glutathione administered Intravenous infusion once monthly for 3 months (Phase I)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Umbilical Cord Blood-Derived Stem Cells and Exosomes

Intravenous infusion of cryopreserved allogeneic umbilical cord blood-derived product containing viable mononuclear cells (including hematopoietic and mesenchymal stem/stromal cells) and exosomes.

Intervention Type BIOLOGICAL

Glutathione

Reduced L-glutathione administered Intravenous infusion once monthly for 3 months (Phase I)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 3-12 years
* Confirmed ASD diagnosis (DSM-5 criteria, supported by ADOS-2)
* Parent/guardian willingness to consider experimental treatments and comply with study requirements
* Ability to attend all scheduled visits

Exclusion Criteria

* Severe allergies to study products
* Significant uncontrolled medical conditions
* Pregnancy or breastfeeding (if applicable)
* Participation in another interventional trial within 30 days
Minimum Eligible Age

3 Years

Maximum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Adia Med of Winter Park LLC

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Larry Powalisz

Role: CONTACT

Phone: 3212312843

Email: [email protected]

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Adia Med ASD Research Study

Identifier Type: -

Identifier Source: org_study_id